Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CytRx, a biopharmaceutical company, has announced positive safety data of ongoing Phase 1b/2 clinical trial with INNO-206 in patients with advanced solid tumors, especially soft tissue sarcomas.
Subscribe to our email newsletter
INNO-206 is a novel conjugate of doxorubicin that binds covalently to albumin, the most abundant protein in blood plasma, and is circulated throughout the body.
Patients received three different dose levels of INNO-206 to determine its maximum tolerated dose in the trial.
The maximum tolerated dose of INNO-206 that delivers a doxorubicin equivalent of 3½ times the standard doxorubicin dose administered to sarcoma patients was determined.
Five patients completed four cycles with INNO-206 at the maximum tolerated dose, of which one showed a partial tumor response and four patients have stable disease.